| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
107,009 |
48,968 |
$6.93M |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
42,058 |
18,466 |
$778K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
9,303 |
8,037 |
$670K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
15,205 |
14,385 |
$445K |
| 88377 |
|
1,079 |
1,066 |
$318K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
7,552 |
5,414 |
$259K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
8,264 |
7,124 |
$251K |
| 87481 |
|
8,464 |
7,364 |
$178K |
| 88342 |
|
9,687 |
9,482 |
$140K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
1,910 |
855 |
$139K |
| 88120 |
|
1,077 |
974 |
$112K |
| 87640 |
|
9,070 |
8,029 |
$67K |
| 87653 |
|
9,114 |
8,063 |
$66K |
| 87500 |
|
8,691 |
7,632 |
$66K |
| 87529 |
|
5,894 |
5,207 |
$57K |
| 88313 |
|
7,654 |
7,455 |
$55K |
| 87496 |
|
5,926 |
5,245 |
$44K |
| 87532 |
|
5,853 |
5,178 |
$41K |
| 88360 |
|
1,450 |
1,424 |
$29K |
| 88112 |
|
3,520 |
3,364 |
$24K |
| 87511 |
|
2,966 |
2,558 |
$19K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
2,417 |
2,104 |
$19K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
1,249 |
1,136 |
$11K |
| 88341 |
|
751 |
747 |
$10K |
| 87482 |
|
740 |
656 |
$10K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
1,257 |
1,141 |
$10K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
1,066 |
952 |
$7K |
| 88142 |
|
268 |
257 |
$2K |
| 87631 |
|
84 |
56 |
$2K |
| 87186 |
|
206 |
189 |
$1K |
| 88141 |
|
122 |
119 |
$1K |
| G2024 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source |
83 |
64 |
$1K |
| 87556 |
|
115 |
104 |
$1K |
| 88312 |
|
155 |
152 |
$1K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
199 |
193 |
$1K |
| 81003 |
|
462 |
449 |
$281.32 |
| 87641 |
|
14 |
12 |
$35.09 |